PDCD1 and neoplasm: By binding to PD-1 and blocking the binding of PD-1 to PD-L1 and PD-L2, sintilimab injection can relieve the immunosuppressive effect, activate the function of T cells, strengthen the immune surveillance and ability of T cells to kill tumors, and generate a tumor immune response (6, 7).